• Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $8,724 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-74 Mln

ImmunoGen Inc. (IMGN) Share Price

$31.23

As on 13-Feb-2024 09:30 EDT

$0.000.00%

  • Prev Close info

    $31.23

  • Day's Openinfo

    $31.23

  • Today's Highinfo

    $31.23

  • Today's Lowinfo

    $31.23

  • Today's Volumeinfo

    --

  • 52 Week rangeinfo

    $3.61 - 31.25

Please wait...

ImmunoGen Inc. (IMGN) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
ImmunoGen (IMGN)
5.33 4.94 111.59 617.93 43.68 42.26 6.96
S&P BSE Sensex*
2.77 1.01 3.52 23.42 14.40 13.97 12.62
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 13-Feb-2024  |  *As on 12-Apr-2024  |  #As on 26-Oct-2023
2023
2022
2021
2020
2019
2018
2017
ImmunoGen (IMGN)
497.78 -33.15 15.04 26.35 6.35 -25.00 214.22
S&P Small-Cap 600
13.89 -17.42 25.27 9.57 20.86 -9.70 11.73
S&P BSE Sensex
18.74 4.44 21.99 15.75 14.38 5.87 27.91

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

ImmunoGen Inc. (IMGN) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of ImmunoGen Inc. (IMGN)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of ImmunoGen Inc. (IMGN)

        President, CEO & Director

        Mr. Mark Joseph Enyedy

        Chief Medical Officer

        Dr. Michael J. Vasconcelles M.D., Ph.D.

        Headquarters

        Waltham, MA

        FAQs for ImmunoGen Inc. (IMGN)

        The total asset value of ImmunoGen Inc. (IMGN) stood at $ 957 Mln as on 30-Sep-23

        The share price of ImmunoGen Inc. (IMGN) is $31.23 (NASDAQ) as of 13-Feb-2024 09:30 EDT. ImmunoGen Inc. (IMGN) has given a return of 43.68% in the last 3 years.

        ImmunoGen Inc. (IMGN) has a market capitalisation of $ 8,724 Mln as on 13-Feb-2024. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of ImmunoGen Inc. (IMGN) is 15.53 times as on 13-Feb-2024, a 3.96% premium to its peers’ median range of 3.13 times.

        Since, TTM earnings of ImmunoGen Inc. (IMGN) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the ImmunoGen Inc. (IMGN) and enter the required number of quantities and click on buy to purchase the shares of ImmunoGen Inc. (IMGN).

        ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.

        The CEO & director of Mr. Mark Joseph Enyedy. is ImmunoGen Inc. (IMGN), and CFO & Sr. VP is Dr. Michael J. Vasconcelles M.D., Ph.D..

        The promoters of ImmunoGen Inc. (IMGN) have pledged 0% of the total equity as on Sep-23.

        ImmunoGen Inc. (IMGN) Ratios
        Return on equity(%)
        -21.38
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0.13
        Dividend yield(%)
        0

        No, TTM profit after tax of ImmunoGen Inc. (IMGN) was $-74 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $8,724.23 Mln
        • Revenue (TTM)revenue-information $287.61 Mln
        • Earnings (TTM) earning-information $-73.52 Mln
        • Cash date-information $605.54 Mln
        • Total Debt info $72.11 Mln
        • Insider's Holding 0.32%
        • Liquidity liquidity Low
        • 52 Week range week-range $3.61 - 31.25
        • Shares outstanding share-outstanding 279,353,984
        • 10 Years Aggregate:

          CFO: $-1,216.67 Mln

          EBITDA: $-975.31 Mln

          Net Profit: $-1,247.80 Mln

        About The Company

        • IPO Date 16-Nov-1989
        • President, CEO & Director Mr. Mark Joseph Enyedy
        • Chief Medical Officer Dr. Michael J. Vasconcelles M.D., Ph.D.
        • Listing key-listing NASDAQ: IMGN
        • Country United States
        • Headquarters headquarters Waltham, MA
        • Website website https://www.immunogen.com
        • Business

          ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting...  folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.  Read more

        share-fund-plan-icon